News

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced that its board approved a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately Rs 9.12 crores, subject to adjustment as per the share purchase agreement. IQGEN-X Pharma Private Limited, incorporated in October 2016, reported a turnover of Rs 348 lacs for the financial year ended March 31, 2026, and is engaged in the business of formulation development for regulated and semi-regulated markets, with the acquisition expected to provide Alivus Life Sciences a wider spectrum to offer end-to-end solutions in the API and CDMO space.

Alivus Life Sciences announced that the Annual General Meeting(AGM) of the company will be held on 8 September 2026.

Net profit of Alivus Life Sciences rose 31.71% to Rs 160.08 crore in the quarter ended June 2026 as against Rs 121.54 crore during the previous quarter ended June 2025. Sales rose 6.41% to Rs 640.41 crore in the quarter ended June 2026 as against Rs 601.85 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales640.41601.85 6 OPM %33.0628.63 - PBDT232.81180.05 29 PBT212.22162.99 30 NP160.08121.54 32 Powered by Capital Market - Live News

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 30 July 2026.

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 30 July 2026.